pumabiotechnology.com (PBYI) - Profit After Payment of Taxes

Puma Biotechnology (PBYI) is expanding its business through tactical alliances with foreign pharma giants to promote its developments globally. The company's operations are based on creating innovative oncology therapies, with profits amounting to 0.03. The stock price action below demonstrates the market trends of the asset, whose drug deliveries rely on an international network of certified pharmacies.

For the long-term investor, the reliability of Puma Biotechnology (PBYI) is determined by its ability to generate a stable cash flow. This metric measures the actual financial result, excluding accounting distortions to assess true profitability. The trend in the company's total net income reflects the effectiveness of the monetization of its primary breast cancer drug. However, a single-product dependency makes this indicator extremely sensitive to market demand. The current stability of the business depends directly on the success of global sales expansion.